NCT02160756View on ClinicalTrials.gov

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-56021927 Softgel Capsule

Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.

DRUG

JNJ-56021927 Tablet Formulation 1

Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.

DRUG

JNJ-56021927 Tablet Formulation 2

Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.

DRUG

JNJ-56021927 Tablet Formulation 3

Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.

Sponsors
All Listed Sponsors
lead

Aragon Pharmaceuticals, Inc.

INDUSTRY

NCT02160756 - Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants | Biotech Hunter | Biotech Hunter